MA71708A - Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1 - Google Patents

Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1

Info

Publication number
MA71708A
MA71708A MA71708A MA71708A MA71708A MA 71708 A MA71708 A MA 71708A MA 71708 A MA71708 A MA 71708A MA 71708 A MA71708 A MA 71708A MA 71708 A MA71708 A MA 71708A
Authority
MA
Morocco
Prior art keywords
antibodies
cd3xmuc16
methods
treating cancer
bispecific
Prior art date
Application number
MA71708A
Other languages
English (en)
French (fr)
Inventor
Alison CRAWFORD
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of MA71708A publication Critical patent/MA71708A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA71708A 2018-06-21 2019-06-20 Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1 MA71708A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862688251P 2018-06-21 2018-06-21
EP24176671.6A EP4424712A3 (en) 2018-06-21 2019-06-20 Methods for treating cancer with bispecific anti-cd3xmuc16 antibodies and anti-pd-1 antibodies

Publications (1)

Publication Number Publication Date
MA71708A true MA71708A (fr) 2025-05-30

Family

ID=67254001

Family Applications (2)

Application Number Title Priority Date Filing Date
MA71708A MA71708A (fr) 2018-06-21 2019-06-20 Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1
MA52962A MA52962B1 (fr) 2018-06-21 2019-06-20 Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA52962A MA52962B1 (fr) 2018-06-21 2019-06-20 Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1

Country Status (26)

Country Link
US (1) US11254752B2 (https=)
EP (2) EP4424712A3 (https=)
JP (1) JP7403480B2 (https=)
KR (1) KR102870971B1 (https=)
CN (1) CN112312970B (https=)
AU (1) AU2019290170B2 (https=)
BR (1) BR112020025476A2 (https=)
CA (1) CA3103887A1 (https=)
CL (1) CL2020003256A1 (https=)
DK (1) DK3810281T3 (https=)
EA (1) EA202190088A1 (https=)
ES (1) ES2984972T3 (https=)
FI (1) FI3810281T3 (https=)
HU (1) HUE067985T2 (https=)
IL (1) IL279251B2 (https=)
MA (2) MA71708A (https=)
MX (2) MX2020013905A (https=)
MY (1) MY202134A (https=)
PH (1) PH12020552115A1 (https=)
PL (1) PL3810281T3 (https=)
PT (1) PT3810281T (https=)
RS (1) RS65886B1 (https=)
SG (1) SG11202012137UA (https=)
TW (2) TW202504917A (https=)
WO (1) WO2019246356A1 (https=)
ZA (1) ZA202007599B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
WO2016161010A2 (en) 2015-03-30 2016-10-06 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
AU2016325630B2 (en) 2015-09-23 2022-11-17 Regeneron Pharmaceuticals, Inc. Optimized anti-CD3 bispecific antibodies and uses thereof
CA3110513A1 (en) 2018-08-31 2020-03-05 Regeneron Pharmaceuticals, Inc. Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
IL300835A (en) * 2020-09-02 2023-04-01 Genmab As Antibody therapy
AU2022214319A1 (en) 2021-01-28 2023-08-03 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cytokine release syndrome
WO2022197907A2 (en) * 2021-03-18 2022-09-22 Memorial Sloan-Kettering Cancer Center Methods for treating gynecologic cancer using combination therapy with anti-muc16 x cd3 multispecific antibodies and vegf inhibitors
EP4397320A1 (en) 2021-08-31 2024-07-10 Nihon Medi-Physics Co., Ltd. Radioactive complex of deglycosylated antibody and radioactive pharmaceutical product
EP4437003A1 (en) * 2021-11-24 2024-10-02 Regeneron Pharmaceuticals, Inc. Methods for treating cancer with bispecific anti-cd3 x muc16 antibodies and anti-ctla-4 antibodies
US20230312718A1 (en) * 2022-01-07 2023-10-05 Regeneron Pharmaceuticals, Inc Methods of Treating Recurrent Ovarian Cancer with Bispecific Anti-MUC16 x Anti-CD3 Antibodies Alone or in Combination with Anti-PD-1 Antibodies
JP2025504795A (ja) 2022-01-10 2025-02-19 ナンチン リーズ バイオラブス カンパニー，リミティド 抗体及びその用途
US20250195645A1 (en) * 2022-03-16 2025-06-19 Daiichi Sankyo Company, Limited Combination of multispecific molecule and immune checkpoint inhibitor
EP4507790A1 (en) 2022-04-11 2025-02-19 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
CN120857940A (zh) 2023-02-17 2025-10-28 瑞泽恩制药公司 对cd3/taa双特异性抗体有反应的诱导型nk细胞

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
PL354286A1 (en) 1999-08-23 2003-12-29 Dana-Farber Cancer Institutedana-Farber Cancer Institute Pd-1, a receptor for b7-4, and uses therefor
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
AU2009288730B2 (en) 2008-08-25 2013-06-20 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
CA2840018C (en) 2011-07-24 2019-07-16 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
AU2016325630B2 (en) * 2015-09-23 2022-11-17 Regeneron Pharmaceuticals, Inc. Optimized anti-CD3 bispecific antibodies and uses thereof
LT3394103T (lt) * 2015-12-22 2023-09-11 Regeneron Pharmaceuticals, Inc. Antikūnų prieš pd-1 ir bispecifinių antikūnų prieš cd20/cd3 derinys, skirtas vėžiui gydyti
TWI910495B (zh) 2016-05-13 2026-01-01 美商再生元醫藥公司 藉由投予pd-1抑制劑治療皮膚癌之方法
JP7066690B2 (ja) 2016-09-23 2022-05-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｍｕｃ１６（ムチン１６）抗体
MY203000A (en) * 2016-10-14 2024-06-01 Xencor Inc Il15/il15r� heterodimeric fc-fusion proteins
BR112019010878A2 (pt) 2016-11-29 2019-10-01 Lindhofer Horst combinação de anticorpos multifuncionais de redirecionamento de células t com moduladores de ponto de verificação imunológico e usos dos mesmos

Also Published As

Publication number Publication date
MA52962B1 (fr) 2024-10-31
JP2021528423A (ja) 2021-10-21
JP7403480B2 (ja) 2023-12-22
CN112312970B (zh) 2025-05-23
EP4424712A2 (en) 2024-09-04
RS65886B1 (sr) 2024-09-30
EP3810281B1 (en) 2024-07-24
TW202504917A (zh) 2025-02-01
TWI890661B (zh) 2025-07-21
WO2019246356A1 (en) 2019-12-26
TW202005985A (zh) 2020-02-01
AU2019290170A1 (en) 2021-01-07
DK3810281T3 (da) 2024-08-19
EP4424712A3 (en) 2024-11-13
CL2020003256A1 (es) 2021-04-30
HUE067985T2 (hu) 2024-12-28
FI3810281T3 (fi) 2024-08-14
CN112312970A (zh) 2021-02-02
MY202134A (en) 2024-04-05
PH12020552115A1 (en) 2021-08-02
CA3103887A1 (en) 2019-12-26
SG11202012137UA (en) 2021-01-28
ES2984972T3 (es) 2024-10-31
MX2025008444A (es) 2025-08-01
MA52962A (fr) 2021-04-28
US11254752B2 (en) 2022-02-22
IL279251B1 (en) 2025-11-01
IL279251A (en) 2021-01-31
BR112020025476A2 (pt) 2021-03-16
IL279251B2 (en) 2026-03-01
PL3810281T3 (pl) 2024-11-04
PT3810281T (pt) 2024-08-02
ZA202007599B (en) 2025-02-26
KR20210023981A (ko) 2021-03-04
AU2019290170B2 (en) 2026-04-02
US20190389966A1 (en) 2019-12-26
MX2020013905A (es) 2021-03-09
KR102870971B1 (ko) 2025-10-16
EP3810281A1 (en) 2021-04-28
EA202190088A1 (ru) 2021-03-22

Similar Documents

Publication Publication Date Title
MA71708A (fr) Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1
EP3752193A4 (en) METHODS OF TREATMENT OF CANCER WITH ANTI-PD-1 ANTIBODIES AND ANTI-CTLA4 ANTIBODIES
EP3752180A4 (en) METHOD OF TREATMENT OF CANCER WITH ANTI-PD-1 ANTIBODIES
MA51631A (fr) Anticorps anti-pd1 et méthodes de traitement
MA44146A (fr) Combinaison d'anticorps anti-pd-1 et d'anticorps bispécifiques anti-cd20/anti-cd3 pour traiter le cancer
EP3826667A4 (en) CLAUDIN6 ANTIBODIES AND METHODS OF TREATMENT OF CANCER
CL2018000728A1 (es) Anticuerpos anti-cd19 humano humanizados y métodos de utilización
MA47604A (fr) Anticorps anti-pd-1 pour le traitement du cancer du poumon
EP3634442A4 (en) METHODS OF TREATMENT AND PREVENTION OF DISEASES
MA47362A (fr) Anticorps anti-tnf, compositions et méthodes pour le traitement du rhumatisme psoriasique actif
MA53506A (fr) Méthodes de traitement du cancer avec des inhibiteurs de pd-l1 à petites molécules
EP3370707A4 (en) METHOD FOR THE TREATMENT OF CANCER, USING COMPOSITIONS OF ANTIBODIES AND CARRIER PROTEINS WITH ANTIBODY PRESERVATION
IL269718A (en) Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer
EP3426777A4 (en) COMBINATION VECTORS AND METHOD FOR THE TREATMENT OF CANCER
MA55717A (fr) Méthodes de traitement du cancer de la prostate avec un anticorps anti-psma/cd3
EP3681498A4 (en) PROCEDURES AND COMPOSITIONS FOR CANCER TREATMENT
EP3870104A4 (en) METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
EP3688023A4 (en) PROCEDURES AND COMPOSITIONS FOR CANCER TREATMENT
EP3638293A4 (en) METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER
EP3968987A4 (en) METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
EP3873205A4 (en) MATERIALS AND METHODS FOR TREATMENT OF CANCER
EP3806845A4 (en) CANNABINOID COMPOSITION AND METHODS OF TREATMENT WITH IT
EP3773625A4 (en) METHODS AND MATERIALS FOR TREATMENT OF CANCER
MA48751A (fr) Paradigme de traitement pour un traitement combiné d'anticorps anti-cd19 et de venetoclax
EP4061846A4 (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tigit antibodies